SG11202006254QA - Methods and combination therapy to treat cancer - Google Patents

Methods and combination therapy to treat cancer

Info

Publication number
SG11202006254QA
SG11202006254QA SG11202006254QA SG11202006254QA SG11202006254QA SG 11202006254Q A SG11202006254Q A SG 11202006254QA SG 11202006254Q A SG11202006254Q A SG 11202006254QA SG 11202006254Q A SG11202006254Q A SG 11202006254QA SG 11202006254Q A SG11202006254Q A SG 11202006254QA
Authority
SG
Singapore
Prior art keywords
methods
combination therapy
treat cancer
cancer
treat
Prior art date
Application number
SG11202006254QA
Other languages
English (en)
Inventor
Patrice A Lee
David Chantry
Shannon L Winski
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of SG11202006254QA publication Critical patent/SG11202006254QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202006254QA 2018-01-10 2018-01-10 Methods and combination therapy to treat cancer SG11202006254QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/013211 WO2019139581A1 (en) 2018-01-10 2018-01-10 Methods and combination therapy to treat cancer

Publications (1)

Publication Number Publication Date
SG11202006254QA true SG11202006254QA (en) 2020-07-29

Family

ID=67218727

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006254QA SG11202006254QA (en) 2018-01-10 2018-01-10 Methods and combination therapy to treat cancer

Country Status (13)

Country Link
US (1) US20200368205A1 (ja)
EP (1) EP3737373A4 (ja)
JP (1) JP2021516215A (ja)
KR (1) KR20200106921A (ja)
CN (1) CN111712243A (ja)
AU (1) AU2018401608A1 (ja)
BR (1) BR112020013912A2 (ja)
CA (1) CA3087844A1 (ja)
IL (1) IL275913A (ja)
MX (1) MX2020007404A (ja)
RU (1) RU2020126340A (ja)
SG (1) SG11202006254QA (ja)
WO (1) WO2019139581A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240139198A1 (en) * 2021-02-10 2024-05-02 Curon Biopharmaceutical (Shanghai) Co., Limited Method and combination for treating tumors
CN114875143B (zh) * 2022-03-25 2024-06-07 中南大学 环状RNA circBRD7在制备鼻咽癌诊断和/或治疗制剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190262A1 (es) * 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
US20160013654A1 (en) * 2014-07-09 2016-01-14 Qualcomm Incorporated Dynamic power supply selection based on system requirements
WO2016011160A1 (en) * 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
AU2016369537B2 (en) * 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof

Also Published As

Publication number Publication date
WO2019139581A1 (en) 2019-07-18
IL275913A (en) 2020-08-31
EP3737373A4 (en) 2021-09-08
MX2020007404A (es) 2020-09-14
US20200368205A1 (en) 2020-11-26
RU2020126340A (ru) 2022-02-10
AU2018401608A1 (en) 2020-07-16
RU2020126340A3 (ja) 2022-02-10
BR112020013912A2 (pt) 2020-12-22
KR20200106921A (ko) 2020-09-15
JP2021516215A (ja) 2021-07-01
CN111712243A (zh) 2020-09-25
EP3737373A1 (en) 2020-11-18
CA3087844A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
IL283838A (en) A method of treating cancer by combined treatment
IL268138A (en) Combinations of cabozantinib and atezolizumab for cancer treatment
IL290695A (en) Combined immunotherapy and cytokine control therapy for cancer treatment
IL254435A0 (en) Optimal combined therapy and its use for the treatment of cancer and autoimmune disease
IL267795A (en) Combined treatment for cancer
IL270511A (en) Combined treatments using niraparib and pembrolizumab for the treatment of cancer
IL274837B1 (en) Combined treatment for cancer
IL275517A (en) Combined methods and treatment of cancer
IL248704A0 (en) Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2
IL254842B (en) Therapeutic preparations and methods for use in cancer treatment
HK1245096A1 (zh) 用於癌症治療的細胞治療劑以及使用該細胞治療劑的聯合治療
IL279591A (en) Cancer treatment methods using combination therapy
IL266993A (en) Combined therapy for cancer treatment
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
IL274343A (en) Treatment methods and maintenance treatment for bladder cancer using gemcitabine
SG11202106295WA (en) Compositions and methods for cancer therapy
IL275913A (en) Methods and combined treatment for cancer treatment
IL263905A (en) Combined cancer treatment
IL281281A (en) Combined treatment for prostate cancer
EP3490971A4 (en) METHOD FOR TREATING AND PREVENTING SIDE EFFECTS OF A CANCER TREATMENT
IL288178A (en) Combined gmci and ddri treatment for cancer
EP3752154A4 (en) Methods and combination therapy to treat biliary tract cancer
GB201820975D0 (en) Methods of cancer treatment
SG11202000881VA (en) Adjuvant therapy for use in prostate cancer treatment
IL253642A0 (en) Combined treatment for cancer